Impact of neoadjuvant chemotherapy on the efficacy of sugammadex for neuromuscular block reversal in ovarian cancer patients: A prospective cohort study
Authors' conclusion
The study indicated that in patients who underwent NAC, the time from sugammadex administration to TOFr ≥0.9, the recovery index, and the extubation time were prolonged.
Study context
- Population
- Ovarian cancer patients undergoing cytoreductive surgery with rocuronium NMB reversed by sugammadex 2 mg/kg at T2
- Participants
- 43 patients
- Exposure
- Neoadjuvant chemotherapy (NAC) vs no NAC before cytoreductive surgery
- Chemon = 21
- Non-chemon = 22reference
- Outcome
- Time from sugammadex administration to TOFR ≥ 0.9
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Time to TOFR ≥0.9 after sugammadex
P < 0.001
Observational data: associations, not effects.
Secondary outcomes
Recovery index · longer in Chemo
P = 0.020
Extubation time · longer in Chemo
P = 0.002
Onset time · prolonged in Chemo
P = 0.001
Clinical duration · shortened in Chemo
P = 0.011
Average rocuronium dosage · increased in Chemo
P = 0.002
Duration of post-anesthesia care unit (PACU) stay
- No significant difference between the two groups
Original publication
Impact of neoadjuvant chemotherapy on the efficacy of sugammadex for neuromuscular block reversal in ovarian cancer patients: A prospective cohort study. J Clin Anesth. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →